Full Text View
Tabular View
No Study Results Posted
Related Studies
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
This study has been completed.
Study NCT01206881   Information provided by Herlev Hospital

First Received on September 13, 2010.   Last Updated on June 30, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
pegylated liposomal doxorubicin
Additional drug interventions recognized in this trial
Cyclophosphamide
Docetaxel
Doxorubicin
Trastuzumab
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Herlev Hospital
Rigshospitalet, Denmark
Odense University Hospital
Aarhus University Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services